Next 10 |
home / stock / eprxf / eprxf news
2024-04-01 17:17:38 ET More on Eupraxia Pharmaceuticals Historical earnings data for Eupraxia Pharmaceuticals Financial information for Eupraxia Pharmaceuticals Read the full article on Seeking Alpha For further details see: Eupraxia Pharmaceuticals&n...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 15, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has closed i...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has priced i...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced the launch of an ove...
2023-08-11 17:52:14 ET Eupraxia Pharmaceuticals press release ( TSX: EPRX:CA ): Q2 net loss of C$8.0 million for the three months ended June 30, 2023, versus C$6.3 million for the three months ended June 30, 2022. Company had cash and cash equivalents of C$19.1 million as ...
2023-08-04 07:43:17 ET Clinical-stage biotechnology company Eupraxia Pharmaceuticals ( TSX: EPRX:CA ) announced a placement of up to 3.1M shares at C$7.00 per share to raise up to C$22M ($16.5M). Company said it intends to use net proceeds from placement towards ongo...
Eupraxia Pharmaceuticals press release ( OTCPK:EPRXF ): Q3 net loss of $4.8 million. The Company had a cash and short-term investments balance of $30.0 million as of September 30, 2022. For further details see: Eupraxia Pharmaceuticals reports Q3 results
Eupraxia Pharmaceuticals Provides Update for Phase 2 Study in Knee Osteoarthritis for Lead Drug Candidate EP-104IAR Canada NewsWire -- Clean Safety Review from Data Safety Monitoring Board Supports Addition of Diabetes Patients into the Trial -- VICTORIA, BC ...
Eupraxia Pharmaceuticals press release ( OTCPK:EPRXF ): Q2 net loss of $6.3 million. The Company had a cash and short-term investments balance of $35.5 million as at June 30, 2022. Management believes it has sufficient resources to fund the Company through to the fourth quarte...
Eupraxia Pharmaceuticals press release (OTCPK:EPRXF): Q1 net loss of $3.8 million for the three months ended March 31, 2022, versus $8.9 million for the quarter ended March 31, 2021. The Company had a cash and short-term investments balance of $25.9 million as at March 31, 2022. Management be...
News, Short Squeeze, Breakout and More Instantly...
Eupraxia Pharmaceuticals Company Name:
EPRXF Stock Symbol:
OTCMKTS Market:
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 15, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has closed i...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has priced i...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced the launch of an ove...